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Background: Breast cancer is the leading malignant disease among western women with incidence increasing
over time. High mammographic density is a well-established risk factor for breast cancer. We explored trends in
mammographic density across birth cohorts to gain further insight into possible time trends in women’s
mammographic density that might explain the historical increase in breast cancer incidence.
Methods: Data derived from two mammography screening programs in Denmark from 1991 to 2001, including on
average 41,091 women from Copenhagen and 52,938 women from Funen aged 50–69. Mammographic density
was assessed qualitatively (fatty or mixed/dense) by senior screening radiologists. The proportion of women with
mixed/dense mammographic density was calculated by age at screening, screening period, and birth cohort. The
Generalized Estimating Equations were used to calculate odds ratios and 95% confidence intervals. All statistical
tests were two-sided.
Results: The proportion of women with mixed/dense mammographic density increased from 45% among women
born in the 1920s to 75-80% among women born in the 1940s. In Copenhagen, the age-adjusted odds ratio (95%
CI) of mixed/dense mammographic density in women born in 1941–42 was 2.48 (2.22-2.76) compared with women
born in 1921–22. In Funen, the age-adjusted odds ratio of mixed/dense mammographic density in women born in
1946–47 was 5.89 (5.32-6.51) compared with women born in 1924–25. Hormone use had a greater impact on
mammographic density in birth cohorts of the 1920s compared with those of the 1940s.
Conclusions: We found suggestive evidence of a birth cohort pattern in mammographic density and an
attenuated impact of hormone use in younger compared with older birth cohorts suggesting that postmenopausal
mammographic density could be linked to changing exposures accumulated over time in women’s lives.Background
Breast cancer is the leading malignant disease among
western women [1]. Denmark has an age-standardised breast
cancer incidence of 101.1 per 100.000 [2], with an increased
trend across birth cohorts [3-5]. Age and mammographic
density are important risk factors for sporadic breast cancer
[6]. Mammographic density is defined as the proportion of
fibroglandular relative to fatty breast tissue [7-9]. Mammo-
graphic density in more than 75% of the breast has been
associated with a four- to six fold increased risk of breast
cancer compared with less than 5% mammographic density
[8,10]. This association between mammographic density* Correspondence: sohe@sund.ku.dk
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reproduction in any medium, provided the orand risk of breast cancer has been confirmed by qualitative
and quantitative measures of mammographic density [8].
Studies have found a decrease in average mammographic
density with increasing age and during menopause [6,11],
an inverse association with parity [12] and body mass
index [6,13,14], and a positive association with hormone
use [14-16]. Women’s mammographic density might vary
across birth cohorts by changes in women’s exposures
over time. We explored the importance of birth year on
women’s mammographic density to investigate the histor-
ical increase in breast cancer incidence.Methods
Screening programs
We obtained mammography data from two independent
organised population-based screening programs in
Denmark conducted at specialised clinics from 1991 toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Denmark in the municipality of Copenhagen in April
1991 and in the county of Funen in November 1993.
The two programs offered biennial screening free of
charge, representing 95,000 women aged 50–69 years
[17]. Personal invitation to screening was based on the
updated central population register since 1968 including
information on personal identification number, histor-
ical addresses, emigration, immigration, and vital sta-
tus for all persons ever residing in Denmark. Women
with breast cancer diagnosis were covered by clinical
mammography programs.
A two-view mammography, craniocaudal and oblique,
was performed at initial screening. Independent double
reading by consensus reading was performed by highly
trained radiologists, who assessed mammographic density
qualitatively into fatty or mixed/dense mammographic
density. Fatty mammographic density were equivalent
to BI-RADS (Breast Imaging Reporting and Data System
(BI-RADS) Atlas, 2008) Density code 1 and part of Density
code 2, and mixed/dense mammographic density equiva-
lent to part of BI-RADS Density code 2, Density code 3,
and Density code 4. Women with fatty mammographic
density and a negative screening were scheduled for
a one-view oblique mammography at the subsequent
mammography screening. Women with mixed/dense
mammographic density and a negative screening were
scheduled for a two-view mammography at the subsequent
screening. Subsequent mammograms were compared with
those from earlier screening. The same procedure was
followed throughout the study period [18,19]. The mam-
mography screening programs for Copenhagen and Funen
complied with quality performance indicators as specified
in European guidelines [18,19].
Data
Data were collected on women participating in any of the
first five invitation rounds in Copenhagen from April 1991
to March 2001, and from Funen any of the first four
invitation rounds from November 1993 to December
2001. The analysis was restricted to this period to ensure
consistency in the assessment of mammographic density. In
Copenhagen, all mammograms were assessed by the same
senior radiologist from 1991–1998, supplemented by an
added senior radiologist from the autumn of 1996, who by
consensus reading assessed all mammograms for the rest of
the study period [20]. In Funen, the same senior radiologist
assessed all mammograms during the study period.
Data contained information on personal identification
number, date of examination, mammographic density (fatty
or mixed/dense), and screening outcome. Both programs
used analog mammography throughout the study period.
The density coding was re-evaluated using data from a
Copenhagen study on long-term breast cancer risk inwomen with false-positive screening test [21]. In total,
118 negative screening mammograms taken prior to
the false-positive screening were re-evaluated. Among
31 women with fatty mammographic density, 32%
(n=10) had BI-RADS code 1, 61% (n=19) BI-RADS
code 2, and 7% (n=2) BI-RADS code 3 at re-evaluation.
Among 87 women with mixed/dense mammographic
density, 1% (n=1) had BI-RADS code 1, 31% (n=27)
BI-RADS code 2, 62% (n=54) BI-RADS code 3, and 6%
(n=5) BI-RADS code 4 at re-evaluation. Manual control of
3 misclassified women revealed they were borderline cases
with changed density status over time.
We analyzed data available on systemically admin-
istered estrogen and combined estrogen-progestogen
associated with increased mammographic density
[14-16]. Data were obtained from the Odense University
Pharmacoepidemiological Database, which contained indi-
vidual level information on reimbursed prescription drugs
purchased in all pharmacies in the city of Odense and sub-
urbs from October 1990, and all of Funen from the end of
1992 [22]. The completeness of the register is high and in-
cludes information on personal identification number, date
of purchase, drug code, commercial name, and prescribed
dose [22]. Never users were defined as women with no reg-
istered purchase of hormones prior to screening. Current
users were defined as women who purchased a quantity of
hormones before attending screening that would last until
14 days before screening. For Copenhagen, data on hor-
mone use was available only for the later part of the study
period and was therefore not included in the analysis.
Statistical analysis
The analysis was restricted to women aged 50–71 years
for Copenhagen and 50–69 years for Funen at the time
of screening. Copenhagen invited all women aged 50–69
years at the beginning of each invitation round resulting in
a higher actual age at screening. Funen invited women aged
50–69 years at the time of invitation. Age, period, and birth
cohort were analysed as categorical variables. Age was clas-
sified into two-year age groups (50–51, 52-53….70-71).
Period was defined by the two-year invitation rounds for
Copenhagen (April 1991 to April 1993,…April 1999 to April
2001) and for Funen (January 1994 to December 1995…
January 2000 to December 2001) to have periods of equal
length. Birth cohort was defined in the diagonals by the
linear relation birth cohort = period-age for Copenhagen
(1921-1922….1949-1950) and Funen (1924-1925….1948-
1949). For each screening program, we constructed a
two-way table between two-year age groups and two-year
invitation rounds (period). The same tables were made for
never and current hormone users from Funen. For simpli-
city, past users were omitted from this analysis.
The probability of mixed/dense mammographic density
was calculated by dividing the total number of screened
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total number of screened women, and 95% confidence
intervals (95% CI) for all probabilities were calculated
using the binominal distribution. The association between
mammographic density and birth cohort, screening age,
and screening period was evaluated within the Generalized
Estimating Equation framework. An exchangeable correl-
ation structure was assumed. As age, period, and birth
cohort are correlated, only two of these variables were
included in each regression model to avoid multicollinearity.
The GENMOD procedure (SAS version 9.1) was used to
calculate crude and adjusted odds ratios (OR) and 95%
confidence intervals (95% CI). Two-sided p-values were
calculated at the <0.05 significance level.
The unique personal identification number issued to
all residents of Denmark was used for the record linkage.
The study was approved by the Danish Data Inspection
Agency, which according to Danish legislation serves as
ethical approval of register-based research.
Results
On average 41,091 women were invited to mammography
screening during each of the first five screening rounds in
Copenhagen (Table 1). Coverage in Copenhagen decreased
from 70% to 61% from the first to the fifth screening round.
Data on mammographic density was available for 99% of
the screened women. In Funen, on average 52,938 women
were invited to mammography screening during each of
the first four screening rounds (Table 1). Coverage in Funen
remained constant at 84% during 1993–2001. Data on
mammographic density was available for 98% of the
participating women.
The proportion of women with mixed/dense mam-
mographic density decreased with increasing age in
Copenhagen and Funen (Figure 1A and 1B). This pattern
was seen for never and current hormone users, although
the decrease was smaller among current than never users
(Figure 1C). In both screening programs, the pattern
across age was the same in all screening periods with a
higher proportion of mixed/dense mammographic density
at a given age in the later compared with the earlier
screening periods (Figure 1D and 1E).The decrease in the
proportion of women with mixed/dense mammographic
density with increasing age was smaller among current
than never hormone users (Figure 1F).
The proportions of women with mixed/dense mam-
mographic density for each birth cohort in Copenhagen
are found in the diagonals of Table 2, where each step-
wise diagonal chain of squares represents a birth cohort.
In Table 2, women born in 1940–1942 were 50–51 years
of age in 1991–1993, 52–53 years in 1993–1995, 54–55
years in 1995–1997, 56–57 years in 1997–1999, and 58–
59 years in 1999–2001. This birth cohort had a relatively
constant probability of mixed/dense mammographicdensity at 64% in 1991–1993, 62% in 1993–1995, 61% in
1995–1997, 61% in 1997–1999, and 63% in 1999–2001.
The birth cohort of 1930–1932 was 60–61 years of age
in 1991–1993, 62–63 years in 1993–1995, 64–65 years
in 1995–1997, 66–67 years in 1997–1999, and 68–69
years in 1999–2001. The probability of mixed/dense
mammographic density in this birth cohort was stable at
45% in 1991–1993, 44% in 1993–1995, 43% in 1995–
1997, 46% in 1997–1999, and 48% in 1999–2001. The
probability of mixed/dense mammographic density was
thus lower in the birth cohorts of 1930–1932 than in the
birth cohorts of 1940–1942 at all ages. This pattern was
consistent across birth cohorts among women of the
same age (Figure 1G and 1H).
Figure 1G shows the proportion of women with mixed/
dense mammographic density by age and birth cohort in
Copenhagen. For each birth cohort, the proportion of
women with mixed/dense mammographic density was
stable across age. However, the proportion of women
with mixed/dense mammographic density increased
from 40-45% in women born in the 1920s to 75-80% in
women born in the late 1940s. Although we did not have
data for all age groups from these two birth cohorts it is
unlikely that the graphs would have overlapped. For
nearly all birth cohorts, the proportion of women with
mixed/dense mammographic density was slightly higher
at the last observed point.
Figure 1H shows the proportion of women with
mixed/dense mammographic density by age group and
birth cohort in Funen. The proportion of women with
mixed/dense mammographic density was lower in the
2nd period and higher in the 4th period, than in the 1st
and 3rd periods. The proportion of women with mixed/
dense mammographic density in Funen increased from
45% among women born in the late 1920s to 75-80%
among women born in the late 1940s.
Figure 1I and Table 3 show the proportion of women
with mixed/dense mammographic density by age, birth
cohort, and hormone use in Funen. The proportion of
never users with mixed/dense mammographic density
was similar to the proportion of all women with mixed/
dense mammographic density, increasing from 45%
among women born in the late 1920s to 75-80% among
women born in the late 1940s. The proportion of
current users with mixed/dense mammographic density
increased from around 70% for women born in the late
1920s to 80-85% for women born in the late 1940s. The
difference in the proportion of women with mixed/dense
mammographic density found between never and
current users born in the late 1920s (45% versus 71%)
had clearly decreased for those born in the late 1940s
(62% versus 75%). Sensitivity analysis restricted to com-
bined estrogen-progestogen users showed similar results
(data not shown).
Table 1 Mammography screening program in the Copenhagen (1991–2001) and Funen (1993–2001) regions, Denmark
Copenhagen
Screening period, Year 1991-93 1993-95 1995-97 1997-99 1999-2001
Target population (TP), N (%) 43092 41159 40037 40304 40865
Coverage by age (years), N (%) 29991 (69.6) 25920 (63.0) 24981 (62.4) 25269 (62.7) 24910 (61.0)
50-54 5779 (58.8) 5737 (54.7) 6668 (57.3) 7200 (52.7) 6918 (50.5)
55-59 6967 (72.8) 6279 (67.9) 6127 (66.4) 6699 (70.2) 7215 (67.1)
60-64 7377 (69.2) 5995 (61.4) 5600 (63.2) 5299 (63.9) 5289 (64.2)
65-711 9868 (75.7) 7909 (67.8) 6586 (63.9) 6071 (68.8) 5488 (67.3)
Data on mammographic density, N (%)
Yes 29991 (98.8) 25920 (99.4) 24981 (99.4) 25269 (99.4) 24910 (99.4)
No2 363 (1.2) 163 (0.6) 157 (0.6) 149 (0.6) 145 (0.6)
Mammographic density, N (%)
- Fatty 15814 (52.7) 13093 (50.2) 11668 (46.7) 10669 (42.2) 8983 (36.1)
- Mixed/dense 14177 (47.3) 12827 (49.2) 13313 (53.3) 14600 (57.8) 15927 (63.9)
Funen
Screening period, Year 1993-95 1996-97 1998-99 2000-01
Target population (TP), N (%) 49666 51985 54198 55905
Coverage by age (years), N (%) 41381 (83.3) 43483 (83.7) 44272 (82.0) 46007 (82.3)
50-54 12755 (86.4) 15046 (89.5) 15052 (84.8) 14755 (85.3)
55-59 10813 (87.4) 10869 (84.5) 11554 (83.6) 13033 (83.7)
60-64 9370 (81.9) 9370 (81.0) 9682 (81.3) 9941 (81.3)
65-69 8416 (75.7) 8198 (75.5) 7984 (74.5) 8278 (76.7)
Data on mammographic density, N (%)
Yes 40253 (97.3) 42767 (98.4) 43564 (98.4) 45275 (98.4)
No2 1128 (2.7) 716 (1.6) 708 (1.6) 732 (1.6)
Mammographic density, N (%)
Fatty 16650 (41.4) 18031 (42.2) 15733 (36.1) 13452 (29.7)
Mixed/dense 23603 (58.6) 24736 (57.8) 27831 (63.9) 31823 (70.3)
1One woman was aged 72 years at screening in the screening period 1993–95 in Copenhagen. 2Women with a positive mammography screening and subsequent
histopathology verified ductal carcinoma in situ (DCIS) or invasive breast cancer.
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of mixed/dense mammographic density and birth cohort,
screening age, and screening period. In Copenhagen, the
age-adjusted OR (95% CI) of mixed/dense mammographic
density in women born in 1941–42 and 1949–50 was 2.48
(2.22-2.76) and 5.41 (4.22-6.94), respectively, compared
with women born in the years 1921–22. In Funen, the
age-adjusted OR of mixed/dense mammographic density
in women born in 1946–47 was 5.89 (5.32-6.51) compared
with women born in 1924–25. Mutually linear adjust-
ments did not alter the results in the multivariate analysis
(data not shown). Although age was a significant predictor
of mixed/dense mammographic density, much smaller ef-
fect sizes for age were seen than for birth cohort. Sensitiv-
ity analysis in subgroups of women with mammographic
density assessments conducted within the same screening
period confirmed the age- and birth cohort patterns found
in the overall data (data not shown), and it therefore seemsunlikely that the age and birth cohort effects were explained
by systematic period effects and fluctuations over time in
the density assessment between screening periods.
Discussion
This study on data from two independent screening
programs showed an increased risk of mixed/dense
mammographic density across birth cohorts. Within a
given birth cohort, the probability of having mixed/dense
mammographic density remained fairly stable across age.
These findings have to our knowledge not been explored
in previous studies.
The Danish population is homogeneous with most
women being Caucasian. Since data for this study derived
from comprehensive registers recall and reporting biases
were unlikely. A limitation of the study was the qualitative
dichotomous measure for mammographic density available
defined as mixed/dense relative to fatty mammographic
Figure 1 Proportion of mixed/dense mammographic density by age (age at diagnosis), period, and birth cohort. Mammography
screening program of Copenhagen (1991–2001) and Funen (1994–2001), Denmark. Copenhagen (1991–2001): A) Proportion of mixed/dense
mammographic density by age group, Copenhagen 1991–2001. D) Proportion of mixed/dense mammographic density by age group and period,
Copenhagen 1991–2001. G) Proportion of mixed/dense mammographic density by age group and birth cohort, Copenhagen 1991–2001. Funen
(1994–2001): B) Proportion of mixed/dense mammographic density by age group, Funen 1994–2001. E) Proportion of mixed/dense
mammographic density by age group and period, Funen 1994–2001. H) Proportion of mixed/dense mammographic density by age group and
birth cohort, Funen 1994–2001. Current and never hormone users, Funen (1994–2001): C) Proportion of mixed/dense mammographic density by
age group, Funen 1994–2001. F) Proportion of mixed/dense mammographic density by age group and period, Funen 1994–2001. I) Proportion of
mixed/dense mammographic density by age group and birth cohort, Funen 1994–2001. Legend: Dotted line; current users, solid line; never users.
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tend to overestimate the degree of density and are less
precise than quantitative measures of mammographic
density [23], subtle changes in mammographic density
in the age-period-cohort modeling could potentially be
masked. To ensure consistency in the density assessment,
the analysis was restricted to a study period where the sameradiologists by consensus reading were in charge of the
density assessment. 14% and 24% of women in Copenhagen
and Funen, respectively, changed mammographic density
category over time within the 10-years of follow-up in our
study. The 10% difference between the two programs might
be explained by a known larger proportion of women in
the ages of menopausal transition 50–54 years in the Funen














50-51, n=7818 64 (63–65) 67 (66–68) 72 (71–73) 76 (75–77) 81 (81–82) 72 (72–73)
52-53, n=16808 56 (55–57) 62 (61–63) 68 (67–68) 73 (72–73) 80 (79–80) 68 (68–69)
54-55, n=14962 54 (53–55) 54 (53–55) 61 (60–61) 66 (66–67) 75 (74–75) 63 (62–63)
56-57, n=13546 50 (49–50) 53 (52–54) 54 (53–55) 61 (60–62) 68 (67–69) 57 (57–58)
58-59, n=12455 48 (47–49) 50 (49–51) 52 (51–53) 54 (53–55) 63 (62–64) 54 (53–54)
60-61, n=12007 45 (44–46) 47 (46–48) 50 (49–51) 53 (52–54) 56 (55–57) 50 (49–50)
62-63, n=11758 43 (43–44) 44 (43–45) 47 (46–48) 48 (47–49) 55 (52–54) 47 (46–47)
64-65, n=11627 43 (42–44) 42 (41–43) 43 (42–44) 47 (46–48) 51 (50–52) 45 (44–45)
66-67, n=11886 42 (41–42) 42 (41–43) 43 (42–44) 46 (45–47) 49 (48–50) 44 (43–44)
68-69, n=12009 42 (41–43) 42 (41–43) 43 (42–44) 43 (42–44) 48 (47–49) 43 (43–44)
70-71, n=6194 41 (40–42) 42 (41–43) 43 (41–44) 45 (44–47) 46 (44–47) 43 (42–44)












50-51, n=23122 73 (72–74) 75 (74–76) 80 (79–81) 84 (83–85) 78 (77–78)
52-53, n=22277 68 (67–70) 65 (64–66) 74 (73–75) 79 (78–80) 72 (71–73)
54-55, n=20506 64 (63–66) 61 (60–63) 68 (66–69) 76 (74–77) 68 (67–68)
56-57, n=18539 60 (59–62) 58 (56–59) 64 (62–65) 71 (69–72) 64 (63–64)
58-59, n=16776 58 (56–59) 56 (54–47) 62 (61–64) 68 (67–69) 61 (60–62)
60-61, n=15664 55 (53–56) 53 (52–55) 59 (57–60) 67 (65–68) 59 (58–59)
62-63, n=14734 50 (49–52) 50 (49–52) 57 (55–59) 64 (63–66) 56 (55–57)
64-65, n=13820 49 (47–51) 45 (44–47) 54 (53–56) 62 (60–64) 53 (52–54)
66-67, n=13065 49 (47–51) 47 (45–49) 49 (47–51) 60 (58–62) 51 (50–52)
68-69, n=12162 46 (45–48) 45 (44–47) 50 (48–52) 55 (53–57) 49 (48–50)
Total 59 (58–59) 58 (57–58) 64 (63–64) 70 (70–71)
Mammography screening program of Copenhagen (1991–2001) and Funen (1994–2001), Denmark.
1The second round of Funen was to some extent affected by film problems during the year 1996 which could result in some inconsistency when comparing
screening round 2 with the other screening rounds.
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program [24]. The proportions of women with changed
mammographic density category in Copenhagen and Funen
were as expected considering the 10-years follow-up period.
Record linkage by the unique personal identification num-
bers ensured correct linkage of records. We find it unlikely
that selection bias affected our results since coverage dif-
fered between the two programs with similar results. How-
ever, we did not have information available on body mass
index (BMI) for the whole cohort and systematic bias could
have occurred, if obese women from younger birth cohorts
were more likely to abstain from mammography screening
than obese women from older birth cohorts, since obesity
is inversely associated with mammographic density [25]. In
a subanalysis of 5134 women with available data on object-
ively measured BMI from the Diet, Cancer, and Health co-
hort study [26], we found no systematic differences acrossbirth cohorts among obese women abstaining from mam-
mography screening (data not shown). The association
between non-participation and women’s educational level
or socio-economic status was found to be U-shaped with a
strong urban–rural gradient in non-participation [24,27,28].
The age-period-cohort modeling in Table 4 was not ad-
justed for reproductive or life style risk factors pertaining to
women’s lives, since we did not have information available
for the whole cohort, wherefore residual confounding can-
not be completely ruled out.
The birth cohort adjusted odds of mixed/dense breasts
across period remained steady in Copenhagen but in-
creased in Funen (Table 4). This period effect in Funen
was likely caused by a lower percentage of women with
mixed/dense mammographic density in the 2nd invitation
round due to temporary film quality problems in 1996
in Funen [18]. In both programs we found elevated
Table 3 Proportion (%) of women with mixed/dense mammographic density by hormone use (HT), screening age,












50-51, n=11858 73 (72–73) 74 (74–75) 79 (79–80) 83 (82–85) 77 (77–78)
52-53, n=10006 66 (65–66) 62 (61–63) 72 (71–73) 78 (77–80) 70 (69–71)
54-55, n=8378 60 (59–61) 56 (55–57) 64 (63–65) 73 (71–74) 64 (63–65)
56-57, n=7599 55 (54–56) 52 (51–53) 59 (57–59) 67 (65–69) 58 (58–59)
58-59, n=7298 53 (52–54) 52 (51–53) 56 (55–57) 62 (60–64) 56 (55–57)
60-61, n=7468 50 (49–51) 47 (46–48) 53 (52–54) 60 (58–62) 53 (52–54)
62-63, n=7422 45 (44–46) 45 (44–46) 51 (50–52) 60 (58–62) 50 (49–51)
64-65, n=7556 45 (44–46) 41 (40–42) 50 (49–51) 57 (55–59) 48 (47–49)
66-67, n=7475 45 (44–46) 42 (41–43) 43 (42–44) 55 (53–57) 46 (45–47)
68-69, n=7227 43 (42–44) 41 (40–42) 45 (44–46) 50 (48–52) 44 (43–45)












50-51, n=3649 76 (75–77) 80 (79–81) 83 (82–84) 88 (86–90) 81 (80–83)
52-53, n=4025 76 (75–77) 75 (74–76) 82 (81–83) 84 (82–86) 79 (78–80)
54-55, n=3788 73 (72–75) 73 (72–74) 78 (77–79) 85 (83–87) 78 (77–79)
56-57, n=3462 71 (70–73) 72 (71–73) 76 (75–77) 82 (80–84) 75 (74–77)
58-59, n=2986 72 (71–73) 66 (65–67) 76 (75–78) 81 (79–84) 74 (73–76)
60-61, n=2511 73 (71–74) 70 (69–72) 72 (71–73) 83 (81–86) 75 (73–76)
62-63, n=2047 69 (68–71) 71 (69–72) 75 (74–77) 78 (76–81) 74 (72–75)
64-65, n=1631 68 (66–69) 63 (61–65) 74 (73–76) 80 (77–83) 72 (70–74)
66-67, n=1414 69 (67–71) 69 (68–70) 71 (69–73) 82 (78–85) 73 (71–75)
68-69, n=1162 66 (64–69) 67 (65–69) 72 (70–74) 76 (72–80) 70 (68–73)
Total 73 (72–73) 72 (71–73) 77 (76–78) 83 (82–83)
Mammography screening program of Funen (1994–2001), Denmark.
Hellmann et al. BMC Cancer 2013, 13:409 Page 7 of 10
http://www.biomedcentral.com/1471-2407/13/409proportions of women with mixed/dense mammographic
density in the latest invitation rounds. From 2000 to 2004,
two projections of the breasts were used increasingly and
became standard in 2004. Since two projections encoded
mixed/dense mammographic density, a concern could
be if this drift seen for all ages during the last screening
round could compensate for a biologically true decline in
mammographic density over age. We therefore restricted
the analysis to the period 1991–2001 where no systematic
changes in screening practice or mammographic density
assessment took place in the two programs, to reduce the
probability that systematic changes in screening practice
could have caused the findings attributed to the age- and
birth cohort effects.
Boyd et al. [11] distinguished between cross-sectional
studies, where mammographic features of different women
are compared, and longitudinal studies on changes in
mammographic density of individual women. Thoughbirth cohort trends in women’s mammographic density
have not been investigated in previous studies, the largest
study on longitudinal measurements from the Breast
Cancer Surveillance Consortium [29] did report a BI-RADS
density distribution across age-groups consistent with the
birth cohort effects found in our study. The Breast Cancer
Surveillance Consortium covered 301,955 women aged 30
to 70+ years. The follow-up time was for half of the women
less than three years from the first to the last mammogram.
Overall, there was no change in the women’s distribution
by BI-RADS density codes between the first and last mam-
mogram, though the short follow-up time should be taken
into account. There was, however, a considerable difference
across age groups consistent with an increase in mam-
mographic density by year of birth. The proportion of
BI-RADS density code 3 or 4 at last mammogram was
64% in women aged 30–39 years, 60% aged 40–49, 40%
aged 50–59, 29% aged 60–69, and 29% in women aged
Table 4 Odds ratios (95% CI) of mixed/dense mammographic density by screening age, period, and birth cohort
Copenhagen N F/MD* Crude odds ratio Adjusted odds ratio Funen N F/MD* Crude odds ratio Adjusted odds ratio
Age2 Age2
50-51 2169|5649 Ref. Ref. 50-51 5125|17997 Ref Ref
52-53 5300|11508 0.87 (0.84-0.90) 0.92 (0.89-0.95) 52-53 6232|16045 0.82 (0.80-0.83) 0.89 (0.86-0.91)
54-55 5548|9414 0.78 (0.76-0.81) 0.89 (0.85-0.92) 54-55 6620|13886 0.74 (0.72-0.76) 0.87 (0.85-0.90)
56-57 5763|7783 0.71 (0.69-0.74) 0.86 (0.82-0.90) 56-57 6749|11790 0.68 (0.66-0.70) 0.88 (0.85-0.91)
58-59 5783|6672 0.67 (0.64-0.69) 0.86 (0.82-0.90) 58-59 6513|10263 0.64 (0.62-0.66) 0.92 (0.89-0.95)
60-61 6015|5992 0.62 (0.60-0.65) 0.85 (0.81-0.90) 60-61 6501|9163 0.60 (0.58-0.62) 0.97 (0.93-1.02)
62-63 6225|5533 0.59 (0.57-0.62) 0.86 (0.82-0.90) 62-63 6519|8215 0.58 (0.56-0.60) 1.05 (1.00-1.10)
64-65 6408|5219 0.55 (0.53-0.58) 0.85 (0.80-0.89) 64-65 6514|7306 0.56 (0.54-0.58) 1.12 (1.07-1.17)
66-67 6685|5201 0.54 (0.52-0.56) 0.86 (0.81-0.91) 66-67 6360|6705 0.56 (0.54-0.58) 1.22 (1.16-1.29)
68-69 6798|5211 0.53 (0.51-0.55) 0.88 (0.83-0.93) 68-69 6183|5979 0.54 (0.52-0.56) 1.30 (1.23-1.37)
70-71 3532|2662 0.50 (0.48-0.53) 0.87 (0.81-0.92) - - - -
Period2 Period2
1991-1993 15814|14177 Ref. Ref. 1994-1995 16100|22959 Ref Ref
1993-1995 13092|12827 0.98 (0.96-1.00) 0.95 (0.93-0.96) 1996-1997 18031|24736 0.84 (0.83-0.86) 0.81 (0.80-0.82)
1995-1997 11668|13313 1.00 (0.98-1.02) 0.94 (0.92-0.96) 1998-1999 15733|27831 0.97 (0.96-0.99) 0.91 (0.90-0.93)
1997-1999 10669|14600 1.01 (0.99-1.04) 0.92 (0.90-0.94) 2000-2001 13452|31823 1.15 (1.13-1.18) 1.05 (1.03-1.07)
1999-2001 8983|15927 1.11 (1.08-1.13) 0.97 (0.95-1.00) - - - -
Birthcohort1 Birthcohort1
1921-1922 1599|1117 Ref. Ref. 1924-1925 1620|1401 Ref. Ref.
1923-1924 3276|2334 1.02 (0.93-1.13) 1.02 (0.93-1.13) 1926-1927 3359|3008 1.01 (0.93-1.11) 1.04 (0.96-1.14)
1925-1926 4508|3258 1.04 (0.94-1.15) 1.05 (0.95-1.16) 1928-1929 4972|4721 1.10 (1.01-1.20) 1.19 (1.09-1.30)
1927-1928 5285|4026 1.11 (1.00-1.22) 1.12 (1.01-1.24) 1930-1931 6579|6518 1.21 (1.11-1.32) 1.35 (1.24-1.48)
1929-1930 6047|4746 1.13 (1.03-1.25) 1.15 (1.04-1.28) 1932-1933 6323|7672 1.42 (1.30-1.54) 1.70 (1.55-1.86)
1931-1932 6166|5315 1.26 (1.14-1.39) 1.28 (1.15-1.42) 1934-1935 6415|8665 1.54 (1.42-1.68) 1.98 (1.81-2.17)
1933-1934 5880|5270 1.32 (1.20-1.46) 1.35 (1.21-1.50) 1936-1937 6573|9729 1.77 (1.63-1.92) 2.40 (2.19-2.63)
1935-1936 5705|5888 1.51 (1.36-1.66) 1.53 (1.37-1.70) 1938-1939 6529|10507 1.99 (1.83-2.17) 2.83 (2.58-3.11)
1937-1938 5547|6556 1.71 (1.55-1.89) 1.71 (1.53-1.90) 1940-1941 6588|12407 2.20 (2.03-2.39) 3.18 (2.90-3.50)
1939-1940 5716|7490 1.91 (1.73-2.10) 1.86 (1.67-2.07) 1942-1943 6638|14842 2.76 (2.55-3.00) 3.90 (3.54-4.28)
1941-1942 4300|7531 2.56 (2.32-2.82) 2.48 (2.22-2.76) 1944-1945 4686|13950 3.27 (3.01-3.55) 4.63 (4.21-5.10)
1943-1944 3270|7371 3.27 (2.97-3.61) 3.12 (2.80-3.48) 1946-1947 2429|9351 4.23 (3.88-4.61) 5.89 (5.32-6.51)
1945-1946 2032|6151 4.40 (3.98-4.87) 4.15 (3.71-4.64) 1948-1949 875|4578 5.93 (5.37-6.55) 7.68 (6.86-8.61)
1947-1948 805|3400 6.21 (5.55-6.95) 5.72 (5.05-6.47) - - - -
1949-1950 90|391 6.22 (4.88-7.92) 5.41 (4.22-6.94) - - - -
Mammography screening program of Copenhagen (1991–2001) and Funen (1994–2001), Denmark.
*F/MD: F=fatty mammographic density; MD=mixed/dense mammographic density.
1Adjusted for screening age.
2Adjusted for birth cohort.
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50–59 was consistent with a decrease in mammographic
density related to changing menopausal status.
Boyd et al. [11] found a 5% decrease in mammographic
density among women premenopausal at first and post-
menopausal at next mammography in a study population
of 202 women, with an excess decrease in mammographic
density of 3% compared with an age-matched group ofwomen remaining premenopausal. McCormack et al. [30]
found a decreased median mammographic density from
20% at first to 12% at third screening among 226 women
aged 50–52 years at recruitment, and a decrease from 15%
to 11% in 155 women aged 53–65 years at recruitment.
Verheus et al. [31] followed 684 women average aged 46.5
years with an average follow-up of 5.5 years, who were
premenopausal at initial screening and postmenopausal at
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menopause from 44% at premenopausal status to 34%
at postmenopausal status. These longitudinal data from
screening populations unanimously showed a moderate
decrease in mammographic density related to changing
menopausal status and moderate changes at later age. In
the Copenhagen data, we did not see a decrease in the
proportion of women with mixed/dense mammographic
density around menopause from age 50–51 to age 52–53
in the four birth cohorts where data were available for
these age groups (Figure 1G). However, based on data
reported by Danish nurses [32] more than half of Danish
women were expected to be postmenopausal at their first
invitation to screening. Further, it is questionable whether
the dichotomous variable in mixed/dense versus fatty
mammographic density would be sensitive enough to detect
a moderate decrease in mammographic density during
menopause. In the Funen data, the trend for ages 50–51
and 52–53 was difficult to follow due to the film problems
in the second invitation round. Nevertheless, our observa-
tion of fairly stable proportions of women with mixed/
dense mammographic density in the postmenopausal ages
was consistent with the moderate density changes seen for
postmenopausal women in other longitudinal studies.
There is a well-established positive association between
hormone use and mammographic density [14-16]. We
found that hormone use had a considerable impact on the
proportion of women with mixed/dense mammographic
density among women born in the late 1920s but less
among women born in the late 1940s. This difference may
be explained by a higher number of hormone related
exposures in younger compared with older birth cohorts
of women, among others changes in postmenopausal
hormone therapy over time could have had an impact.
A higher number of cohort borne breast cancer risk factors
in younger compared with older birth cohorts of Danish
women has previously been linked to the increasing breast
cancer incidence across birth cohorts of women over time
in Denmark [5]. Changes over time in native Danish
women’s reproductive pattern, increasing obesity, and
sedentary lifestyle could be proxies for increased sex- and
growth hormones levels potentially influencing changes in
women’s mammographic density [4,6].
The results of the current study must be interpreted
with care and warrant future replication in larger individual
level data with longer follow-up and with preferable a quan-
titative measure for mammographic density and adjustment
for reproductive and life style covariates.
Conclusions
Data from two large independent population-based
mammography screening programs showed an increased
proportion of women with mixed/dense mammographic
density from 45% in birth cohorts of the late 1920s to75-80% in birth cohorts of the late 1940s. Hormone
use had a greater impact on women’s mammographic
density in birth cohorts of the 1920s and less in birth
cohorts of the 1940s. The birth cohort pattern and the
attenuated impact of hormone use suggest that mam-
mographic density in postmenopausal age might be
linked to changing exposures over time accumulated in
women’s lives.
The results must be interpreted with care and should
be replicated in future studies.
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